NanoViricides Q1 Loss Widens to $5.7M; Going-Concern Doubt and ATM Sales Begin
NNVC sits 45% above its 52-week low of $0.85 on light trading volume (0.2× avg).
Summary
NanoViricides posted a $5.7 million quarterly loss as clinical trial spending ramped up, disclosed substantial doubt about its ability to continue as a going concern, and began small ATM share sales in November.
Key Events · Earnings and Guidance · NNVC
-
Quarterly Loss Widens Sharply
Net loss was $5,742,936, or $0.23 per share, versus $1,785,058, or $0.10 per share, a year earlier.
-
Trial Costs Drive R&D Surge
Research and development expense rose to $4,697,186 from $993,066, driven by the Mpox and Ebola Phase II clinical trials in the DRC.
-
Going-Concern Warning Disclosed
Cash of $2,575,227 plus the $3 million line of credit will not fund planned operations for at least 12 months; substantial doubt exists about continuing as a going concern.
-
ATM Sales Have Begun
From November 11 to November 13, 2026 the company sold 3,051 shares at an average of $1.40 for about $4,000 in net proceeds under its D. Boral at-the-market program.
Analysis · NNVC · Life Sciences
The loss more than tripled year over year as the Mpox and Ebola Phase II trials in the DRC moved into execution, and management now says cash plus the $3 million line of credit will not fund operations for 12 months. With only $2.6 million of cash against $3.2 million of current liabilities, the company depends on raising more money. It has already started selling into its at-the-market program, though the first three days raised only about $4,000, so the funding gap is real and near-term.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NNVC was trading at $1.23 on NYSE in the Life Sciences sector, with a market capitalization of approximately $31.7M. The 52-week trading range was $0.85 to $1.93. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.